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ARTICLE
Deletions in CCM2 Are a Common Cause of Cerebral Cavernous
Malformations
Christina L. Liquori, Michel J. Berg, Ferdinando Squitieri, Tracey P. Leedom, Louis Ptacek,
Eric W. Johnson, and Douglas A. Marchuk
Cerebral cavernous malformations (CCMs) are vascular abnormalities of the brain that can result in a variety of neu-
rological disabilities, including hemorrhagic stroke and seizures. Mutations in the gene KRIT1 are responsible for CCM1,
mutations in the gene MGC4607 are responsible for CCM2, and mutations in the gene PDCD10 are responsible for
CCM3. DNA sequence analysis of the known CCM genes in a cohort of 63 CCM-affected families showed that a high
proportion (40%) of these lacked any identifiable mutation. We used multiplex ligation-dependent probe analysis to
screen 25 CCM1, -2, and -3 mutation–negative probands for potential deletions or duplications within all three CCM
genes. We identified a total of 15 deletions: 1 in the CCM1 gene, 0 in the CCM3 gene, and 14 in the CCM2 gene. In
our cohort, mutation screening that included sequence and deletion analyses gave disease-gene frequencies of 40% for
CCM1, 38% for CCM2, 6% for CCM3, and 16% with no mutation detected. These data indicate that the prevalence of
CCM2 is much higher than previously predicted, nearly equal to CCM1, and that large genomic deletions in the CCM2
gene represent a major component of this disease. A common 77.6-kb deletion spanning CCM2 exons 2–10 was identified,
which is present in 13% of our entire CCM cohort. Eight probands exhibit an apparently identical recombination event
in the CCM2 gene, involving an AluSx in intron 1 and an AluSg distal to exon 10. Haplotype analysis revealed that this
CCM2 deletion occurred independently at least twice in our families. We hypothesize that these deletions occur in a
hypermutable region because of surrounding repetitive sequence elements that may catalyze the formation of intragenic
deletions.
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Cerebral cavernous malformations (CCMs) are congenital
vascular anomalies of the CNS, with an incidence in the
general population of 0.1%–0.5%.1 The lesions are char-
acterized by grossly enlarged blood vessels consisting of a
single layer of endothelium and without any intervening
neural tissue, ranging in size from a few millimeters to
several centimeters.1–3 CCMs usually present clinically dur-
ing the 3rd to 5th decade of life as hemorrhagic stroke,
seizures, recurrent headaches, and/or focal neurologic
deficits.4,5 Magnetic resonance imaging (MRI) can detect
these lesions and is the only tool available that can detect
this clinically silent lesion.
Familial forms of CCM are inherited in an autosomal
dominant fashion, with three known loci on chromosomes
7q21.2 (CCM1 [MIM 116860]),6–8 7p13 (CCM2 [MIM
603284]),9 and 3q25.2-q27 (CCM3 [MIM 603285]).9 The
disease gene responsible for CCM1 encodes KRIT1 (KREV
interaction trapped 1).10,11 The disease gene for CCM2 is
MGC4607; it encodes malcavernin.12,13 The disease gene
for CCM3 encodes PDCD10 (programmed cell death 10).14
With the recent identification of the CCM3 gene, we
noted an apparent discrepancy in the relative frequencies
of mutations in the three CCM genes between the values
originally predicted by linkage in families and the values
subsequently obtained by DNA sequence–analysis screens
of probands. On the basis of the linkage results of 20 CCM-
affected families, Craig et al. predicted that CCM1 would
account for 40% of all familial CCM cases, CCM2 would
account for 20%, and CCM3 would account for 40%.9
Although the frequency of identified mutations reported
in different patient cohorts for both CCM1 and CCM2
appeared to support the disease frequency based on the
initial linkage data,11–13,15–17 the frequency of mutations in
CCM3 was found to be lower than expected (!10%). On
the basis of the results from separate screens, ∼30% of
probands with CCM had no mutation detectable by se-
quence analysis.18,19 These data suggest either that another
CCM gene exists or that a significant fraction of CCM
mutations are not found by routine DNA sequence anal-
ysis. Potential mutations that would be undetected by se-
quence analysis include mutations within regulatory re-
gions not included in routine sequencing, as well as larger
genomic insertions, deletions, or duplications.
We hypothesized that some or most of the probands
with no mutations detected by routine sequencing could
be accounted for by large genomic deletions or duplica-
tions and that these genomic rearrangements would ac-
count for the discrepancy between the predicted and ob-
served genotype frequencies. The multiplex ligation-de-
pendent probe amplification (MLPA) assay is designed to
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Figure 1. Representative chromatograms from MLPA analysis of
CCM1 and CCM2. A, Results for control individual with peaks cor-
responding to CCM1 and CCM2 exonic probes. There are two probes
to CCM2 exon 2 (5′ and 3′) and one probe to a region 690 bp
upstream of CCM2 exon 1 (“upstream”). All unlabeled peaks rep-
resent the control peaks resulting from the amplification of probes
located on different chromosomes. B, Chromatogram from CCM-
affected proband 254, showing the relative reduction in peak area
of probes hybridizing to exons 5 and 6 of CCM2. Arrows mark the
deleted CCM2 exons. C, Chromatogram from CCM-affected proband
186, showing the relative reduction in peak area of probes hy-
bridizing to exons 2–10 of CCM2. This represents the common CCM2
deletion spanning CCM2 exons 2–10. Arrows mark the deleted CCM2
exons.
Figure 2. Segregation of deletion with disease in family 186.
Blackened symbols show affected individuals; blackened dots in-
dicate carrier status (by microsatellite marker disease haplotype);
unblackened symbols depict healthy individuals with normal MRI
results. The top band is a PCR product through use of primers
spanning the CCM2 exons 2–10 deletion, and only those individuals
who harbor the deletion will show this band. The bottom band is
a control PCR product (CCM1 exon 2), to ensure appropriate DNA
quality and quantity in the multiplex PCR. A 100-bp ladder was
used for sizing, with the brighter band indicating 600 bp.
screen for exonic and whole-gene deletion or duplication
events. MLPA has been used to identify deletions and du-
plications in a variety of inherited diseases.20–22 In the pre-
sent study, we used MLPA to screen a panel of probands
for deletions or duplications within the three known CCM
genes. The panel consisted of probands who were nega-
tive, on DNA sequence analysis, for mutations within the
CCM1, CCM2, and CCM3 genes.
Material and Methods
Study Subjects
The population for the present study consists of 63 non-Hispanic
probands with CCM, as well as 255 additional affected and un-
affected family members. Each of the probands received a positive
diagnosis of CCM through MRI and had multiple lesions and/or
at least one other family member with a CCM lesion confirmed
by MRI. These criteria have been used by us11,12 and others9,13,14,
23 as strong indicators of the inherited form of CCM. This partic-
ular CCM cohort does not include any probands with the common
(founder) Hispanic CCM1 mutation (c.1363CrT; p.Q455X).11
Blood samples were obtained from all individuals in the study
after receipt of informed consent, and DNA was prepared from
these samples through use of standard methods.
Mutation Analysis
Coding exons of the KRIT1 (CCM1), MGC4607 (CCM2), and
PDCD10 (CCM3) genes were amplified using primers described
elsewhere.11,12,18 Exons were sequenced using the Big Dye Termi-
nator chemistry version 1.1 and were run on the ABI PRISM 3100
or 3730 (Applied Biosystems). Sequence tracings were analyzed
using Sequencher 4.1.4 (Gene Codes).
MLPA Analysis
The MLPA CCM test kit (SALSA P130 and P131) was obtained
from MRC-Holland. The P130 probe mix contains MLPA probes
for 8 of the 19 exons of CCM1 and for all 10 exons of CCM2,
with two probes for exon 2 of CCM2 and one probe located 690
bp proximal to exon 1 of CCM1. The P131 probe mix contains
probes for an additional 9 of the 19 exons of CCM1 and for 8 of
the 9 exons of CCM3, with two probes for exon 1 of CCM3. There
are currently no probes for exons 3 and 7 of CCM1 or exon 8 of
CCM3.
MLPA was performed on those probands who were negative,
by sequence analysis, for mutations in CCM1, CCM2, and CCM3.
Each reaction set included three control samples: two unaffected
individuals and one CCM-affected person with a known muta-
tion detectable by sequence analysis. MLPA was performed twice
on all deletion-positive probands. For additional confirmation of
deletions, MLPA was also performed on a second MRI-positive
family member, when available. In the validation screen, only
the relevant probe mix was used (P130 for any CCM2 deletions;
P130 and P131 for any CCM1 deletions).
MLPA was performed according to the protocol supplied, by
use of 100–300 ng DNA sample per reaction. Volumes of all re-
actions were halved, except in the DNA denaturation step, when
samples were diluted to 7 ml with Tris-EDTA. Samples were run
on an ABI PRISM 3100 or 3730, and the data were analyzed with
GeneMapper version 3.5 (Applied Biosystems). Quantification of
copy number was performed as recommended by MRC-Holland,
by use of both visual inspection and normalized peak-area cal-
culations. For the visual inspection, peak heights were compared
between the sample and controls, to find any alteration in relative
peak heights within the test sample (fig. 1). For the normalized
peak-area calculations, each peak area was normalized by dividing
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Figure 3. PCR across the deletion of CCM2 exons 2–10. PCR by
use of primers in intron 1 and distal to exon 10 resulted in the
same size band in all eight probands who had a deletion of CCM2
exons 2–10 as detected by MLPA. The top band (839 bp) is a PCR
product through use of primers spanning the deletion, and only
those individuals who harbor the deletion will show this band.
The bottom band is a control PCR product (CCM1 exon 2), to ensure
appropriate DNA quality and quantity in the multiplex PCR. A 100-
bp ladder was used for sizing, with the brighter band indicating
600 bp. ctrl p Control.










177 Yes Yes None
201 Yes Yes None
219b Yes Yes CCM2 1
238b,c Yes Yes CCM2 2–10
249b,c Yes Yes CCM2 2–10
254b,c Yes Yes CCM2 5–6
258 Yes Yes None
290 Yes Yes None
302c Yes Yes CCM2 2–10
307c Yes Yes CCM2 2–10
312b,c Yes Yes CCM2 2–10
326b Yes Yes CCM2 2
2567 Yes Yes None
2696 Yes Yes None
32 Yes NA CCM2 1–2
207 Yes NA None
1000 Yes NA None
5030b Yes NA CCM1 5–19
186b,c Yes No CCM2 2–10
224c Yes No CCM2 2–10
202 No Yes CCM2 2
239 No Yes None
245 No Yes CCM2 1–2
261 No Yes None
2607c No NA CCM2 2–10
a NApnot available.
b Results confirmed by MLPA of a second affected family member.
c Results confirmed by PCR on proband.
the individual peak area by the total peak area of all peaks for
that sample. Then, for each exon, the normalized peak area of
the sample was divided by the averaged normalized peak area of
the controls. By definition, ratios with a range of 0.45–0.7 indicate
a deletion of that exon, and ratios with a range of 1.3–1.6 indicate
a duplication of that exon.
PCR Analysis of CCM2 Deletions
For deletions spanning regions of the CCM2 gene, long-range PCR
was performed using the Expand 20 kb PLUS PCR System (Roche
Applied Science) following the protocol supplied. A series of for-
ward primers mapping within intron 1 and a series of reverse
primers in the intergenic region distal to exon 10 were used to
map the precise breakpoints for the deletions spanning exons 2–
10.
The primers CCM2i1 J F (5′-GGGACCTCTGTTTTACAGGATAT-
AGAAT-3′) and CCM2outside R4 (5′-AGATACCAGACTATATCAT-
GCTGCTACAAC-3′) generated an 839-bp product that spanned
the deletion of exons 2–10 of the CCM2 gene (figs. 2 and 3). For
this specific amplification, a control set of primers (CCM1 exon
2) was included in the reaction, to ensure appropriate DNA qual-
ity and quantity and to confirm that any negative result from
the J F and R4 primers was not due to failure of the PCR itself.
The PCR was performed using standard conditions (200 mM
dNTPs, 10 mM tris-HCl [pH 9.0], 50 mM KCl, 0.1% Triton X-100,
0.01% [w/v] gelatin, 1.5 mM MgCl2, 0.4 mM each primer, 0.1 U
Taq [Invitrogen]), with 35 cycles of 10 s at 94C, 30 s at 60C,
and 3 min at 72C.
The primers CCM2i4 F (5′-CTAAGGAGTACATGTGTGAATTTT-
ATGAAG-3′) and CCM2i6 R (5′-AAAACTAAGATGACTTTCAGGG-
ACATAGT-3′) generated an ∼4-kb product that spanned the dele-
tion of exons 5–6 of the CCM2 gene. The PCR and cycling con-
ditions were performed, as recommended by Roche, by use of the
Expand 20 kb PLUS PCR System.
Microsatellite Analysis of CCM2 Haplotypes
Haplotypes were generated for all available members of the eight
families with the CCM2 exons 2–10 deletion. Genotypes for each
marker were performed using standard methods. Marker CL7N4
is a (GT)n dinucleotide repeat and was amplified using the forward
primer 5′-ATCACCTTGGGGGTTAGGAT-3′ and the reverse primer
5′-GTGATGCAATGGGAAGGAGT-3′. Marker CL7N5 is a (GA)n di-
nucleotide repeat and was amplified using the forward primer 5′-
CCACCTTCTTGAGGGAACAG-3′ and the reverse primer 5′-ACT-
CATGTGGGCCAATCTCT-3′.
Results
Sequence Analysis of Probands with CCM
We initially performed DNA sequence analysis of the three
known CCM genes—CCM1 (KRIT1), CCM2 (MGC4607),
and CCM3 (PDCD10)—on a cohort of 63 probands with
CCM. We identified 24 mutations in the CCM1 gene, 10
mutations in the CCM2 gene, and 4 mutations in the
CCM3 gene. Most of these results have been reported else-
where.11,12,15,18 The results of this mutation survey showed
that the relative mutation frequencies of the three CCM
genes were 38% for CCM1, 16% for CCM2, and 6% for
CCM3. The remaining 25 probands (40%) lacked any mu-
tation identifiable through use of DNA sequence analy-
sis. In light of this observation, we wanted to determine
whether any of these 25 “mutation-negative” probands had
other types of mutations not detectable by sequence anal-
ysis, such as large deletions or duplications, which might
reconcile the discrepancy between predicted and observed
genotype frequencies.
Detection of CCM Deletions by MLPA
Using MLPA, we screened our panel of 25 mutation-neg-
ative probands for deletions and duplications within the
three known CCM genes (table 1). No duplications and
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% No. % No. % No.
Sequence 38.1 24 15.9 10 6.3 4
Deletion 1.6 1 22.2 14 0 0
Total 39.7 25 38.1 24 6.3 4
NOTE.—Results from a panel of 63 subjects.
15 deletions were identified (fig. 1 and table 1). One de-
letion was in the CCM1 gene, and 14 deletions were in
the CCM2 gene. When appropriate samples were available,
each of the deletions was confirmed by MLPA in an ad-
ditional affected family member. We used long-range PCR
for confirmation of the deletions spanning CCM2 exons
2–10 and spanning CCM2 exons 5–6. The PCR also dem-
onstrated that the deletion cosegregated with the disease
in families 186, 224, 238, 249, 302, and 312 (fig. 2 and
data not shown). Combining the deletion screen results
with our previous DNA sequencing results, in our panel
of 63 probands, we found a mutation frequency of 40%
(25 of 63) for CCM1, 38% (24 of 63) for CCM2, 6% (4 of
63) for CCM3, and 16% (10 of 63) who lacked any iden-
tifiable mutation (table 2).
A Common Deletion in CCM2
Interestingly, 12 of the 14 identified CCM2 deletions in-
cluded exon 2, with 8 of these spanning exons 2–10 (fig.
4A). To determine whether the deletions spanning exons
2–10 represent a common deletion in the CCM2 gene, we
attempted to map the precise breakpoints for each dele-
tion. We employed long-range PCR, using a series of for-
ward primers mapping within intron 1 and a series of
reverse primers in the intergenic region distal to exon 10.
One pair of primers amplified a 6.5-kb band that provided
the approximate location of the deletion breakpoints. Fur-
ther PCR experiments through use of additional primers
that more closely flanked the predicted breakpoints re-
sulted in an amplification product of the same size for
each of the eight probands with the exons 2–10 deletion
(fig. 3). The deletion in all eight families spans 77.6 kb.
Sequence analysis of the resulting PCR products identi-
fied the proximal breakpoint within an AluSx repeat map-
ping in intron 1 (chr7:45024885–45025183) and the distal
breakpoint within an AluSg repeat in the intragenic region
(chr7:45101654–45101952) (fig. 4A and 4B). DNA sequence
analysis confirmed that each of the eight probands har-
bored an apparently identical deletion, since the sequence
within the “hybrid” Alu repeat at the deletion junction
was identical in each (fig. 4B).
All eight of these probands/families are reported to be
non-Hispanic whites, without any obvious shared ethnic-
ity. We performed SNP haplotype analysis to determine
whether this identical deletion was due to a founder effect.
We used long-range PCR to amplify eight known SNPs in
cis with the deletion: six mapping within a 4-kb region
proximal to the deletion and two mapping within a 2.3-
kb region distal to the deletion (fig. 4B). All of the pro-
bands shared the same haplotype immediately flanking
the deletion, but this haplotype (GGAAGCGC) included
the most common allele for each SNP. Furthermore, these
SNPs are in nearly complete linkage disequilibrium with
each other, with D′ values ranging from 0.86 to 1 (Inter-
national HapMap Project). Thus, these data could not for-
mally distinguish between a common founder for all eight
families and the possibility that the deletion had occurred
more than once on a relatively common SNP haplotype.
To further investigate the possibility of a common foun-
der, we examined the eight families for the more infor-
mative class of microsatellite repeats, choosing simple se-
quence repeats that mapped very near the deletion break-
points. These data were consistent with at least two sep-
arate microsatellite haplotypes flanking the deletion (fig.
5).
The microsatellite haplotype data demonstrated that
this common deletion spanning CCM2 exons 2–10 had
occurred independently at least twice in this limited co-
hort of CCM-affected families, suggesting that, in the his-
tory of CCM across the globe, this deletion may have oc-
curred multiple times. Since the haplotypes differ only on
the distal side of the deletion, an alternate explanation
would be that there is an ancient founder and that these
differences are due to ancestral recombination events dis-
tal to the deletion. According to the sequence deposited
in the University of California–Santa Cruz Human Ge-
nome Bioinformatics database, these particular AluSx
(chr7:45024885–45025183) and AluSg (chr7:45101654–
45101952) repeats share 83% homology. Alignment of
these particular repeat elements shows stretches of iden-
tity that might catalyze the recombination event (fig. 4C),
with the central region of predicted recombination con-
taining two of the longest stretches of homology.
We further hypothesized that sequence variation might
exist within these AluSx and AluSg repeats that would in-
crease their sequence homology and thus make them even
more prone to the deletion-causing recombination event.
Sequencing of 58 control alleles resulted in the identifi-
cation of a novel SNP within the AluSx element and con-
firmation of a SNP (rs6955183), noted elsewhere (dbSNP),
within the AluSg element. The alleles at these SNPs are in
nearly complete linkage disequilibrium with each other,
and the haplotype containing the minor alleles decreases
the homology between the two Alu elements. The CCM2
deletion occurs on the more common haplotype, which
increases the overall homology between the two elements,
albeit only slightly.
Discussion
Using MLPA, we determined that many of the CCM mu-
tations undetected by routine DNA-based sequence anal-
ysis could be accounted for by large genomic CCM dele-
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Figure 4. Large deletions within CCM2. A, Schematic diagram of the CCM2 gene and the 14 CCM2 deletions that were identified. The
CCM2 gene is depicted with each exon shown as a white box with the corresponding exon number and each intron shown as a line.
Thick black lines below the gene depict each of the CCM2 deletions, with the solid portion showing the minimal extent of the deletion
and the broken portion showing the maximal extent of the deletion. SINE and LINE elements located near the breakpoints of the
common exons 2–10 deletion are depicted as gray boxes above the CCM2 gene, with orientation of each element indicated by the
arrowhead. The black triangles indicate the location of the breakpoints in the common deletion spanning CCM2 exons 2–10. Not drawn
to scale. B, Schematic diagram of the recombinant Alu element in the common CCM2 deletion and surrounding region. The recombinant
Alu element is shown as a box, with the AluSx and AluSg halves indicated. Nearby SNPs are also shown. A more detailed version of
the recombinant Alu element is shown below. White indicates regions where the sequence is specific to the AluSx, black indicates
regions where the sequence is specific to the AluSg, and gray indicates regions where the sequence is identical between the AluSx and
the AluSg. Base-pair positions are shown above the box. C, Sequence homology between the parental AluSx (chr7:45024885–45025183)
and AluSg (chr7:45101654–45101952). White boxes indicate identical base pairs, gray boxes indicate different base pairs, and black
boxes indicate the location of two SNPs. The carat represents a SNP in AluSx (chr7:45025035GrA), and the asterisk (*) represents SNP
rs6955183 in AluSg.
tions. We identified deletions in 60% (15 of 25) of our
probands in whom mutations had not been previously
identified. Deletions, especially in the CCM2 gene, ac-
count for a significant portion of the undetected muta-
tions in our panel. It is possible that a few of these un-
identified mutations are single-exon deletions of either
CCM1 exon 3, CCM1 exon 7, or CCM3 exon 8, since these
exons are not included in the MLPA assay. The fact that
16% (10 of 63) of CCM mutations still remain unidentified
suggests either that the remaining mutations are in regions
not examined in routine DNA sequencing or that there
may be an additional CCM gene(s).
The inclusion of the deletion-screen results with our
previous DNA sequencing results altered the observed fre-
quencies of CCM1, -2, and -3 mutations. The discrepancy
between predicted and observed mutation frequencies is
now even more pronounced. With the identification of
only one deletion in the CCM1 gene, the frequency (40%)
of CCM1 mutations in our panel matches the frequency
predicted by linkage (40%).9 Although deletions had been
identified in the CCM3 gene,14 we did not find any CCM3
deletions or duplications within our panel. Thus, the fre-
quency of CCM3 mutations (6%) in our cohort is much
lower than the 40% predicted in the initial linkage screen.9
The overwhelming majority (93%) of the deletions in our
panel were found in the CCM2 gene, indicating that the
prevalence of CCM2 may be much higher than previously
suspected. Deletions had also been identified in the CCM2
gene.13 The inclusion of the deletion data increases the
frequency of CCM2 mutations in our panel to 38%, nearly
double that of the original prediction (20%)9 and approx-
imately equal to the frequency of CCM1 mutations. Of
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Figure 5. Schematic representation of affected haplotypes for
families with the CCM2 exons 2–10 deletion. Each haplotype is
represented by an unblackened bar, with the affected alleles for
each marker shown within the bar. The location of the deletion is
shown as “del” with a blackened triangle above the bar. Marker
names are listed above their associated alleles, and family numbers
are listed to the left of their associated haplotypes. For marker
D7S2528, allele 2 is 306 bp. For marker D7S2427, allele 10 is 222
bp. For marker D7S2436, allele 4 is 262 bp. For marker D7S621,
allele 5 is 274 bp and allele 7 is 266 bp. For marker CL7N4, allele
1 is 240 bp and allele 3 is 236 bp. For marker CL7N5, allele 2 is
191 bp and allele 6 is 183 bp. For marker D7S626, allele 6 is 371
bp, allele 7 is 367 bp, allele 8 is 363 bp, and allele 11 is 351 bp.
The distance (in kb) of each marker from the deletion is shown
at the top. Not drawn to scale.
the patients in our panel, ∼78% have mutations in either
the CCM1 or CCM2 genes, whereas mutations in the CCM3
gene appear to be relatively rare.
We identified 8 probands with a deletion spanning
CCM2 exons 2–10, and this specific mutation is found
in 13% (8 of 63) of our CCM cohort. All eight probands
with this deletion have the same breakpoints within an
AluSx in CCM2 intron 1 and an AluSg distal to CCM2
exon 10. This common CCM2 deletion can be identified
by a simple PCR assay through use of primers that flank
the deletion breakpoints. The deletion occurred inde-
pendently at least twice in our limited cohort, suggesting
that it may have occurred many more times worldwide.
Nonetheless, we cannot rule out the existence of a foun-
der effect in specific populations. The deletion is likely
catalyzed by a hypermutable region because of surround-
ing repetitive sequence elements.
Two SNPs within these Alu elements decrease the ho-
mology of the Alu sequences to each other and may re-
duce the chance of recombination between these two el-
ements. The large CCM2 deletion in each of the eight
families in this panel occurred on the more common hap-
lotype, which contained the alleles with increased ho-
mology between the two Alu elements. It is interesting to
note that, whereas there are three AluSx elements in the
immediate vicinity of the intron 1 breakpoint, the AluSx
(chr7:45024885–45025183) is more homologous to the
AluSg (chr7:45101654–45101952) distal to exon 10 than
to any of its neighboring AluSx elements.
This study documents that large deletions in the CCM2
gene represent a major cause of CCM. These deletions have
heretofore been missed by routine DNA sequence-based
mutation screens. In our panel, deletions within the CCM2
gene account for 22% of all identified CCM mutations
(table 2). In addition, the common exons 2–10 deletion
itself accounts for 13% of all identified CCM mutations
in our panel. Thus, deletion screening should be per-
formed on all probands with CCM, to increase the detec-
tion rate of CCM mutations. The common CCM2 exons
2–10 deletion can be identified using the simple PCR-
based amplification assay.
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